United Therapeutics Corporation
NASDAQUTHR cost to borrow surges 114% over the past week to 0.49%, though still at low historical levels. Short interest fell 11.2% in the same period as availability remains extremely high at 2,630%.
Snapshot as of 22 Jun 2026
United Therapeutics is heading into the back half of May with a notable divergence: short sellers are retreating at the same time a key analyst is turning more bullish. Short interest has been unwinding steadily for a…
United Therapeutics enters the post-earnings period with an unusual alignment: options traders turned the most bullish they've been all year on the day the CEO and CFO were selling stock at the open. The insider angle…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for UTHR — free to start on ORTEX.
Sign up for free →Open UTHR on ORTEX